The SBC Catalyser Programme
Do you have a winning commercialisation strategy?
APPLICATIONS CLOSED (21 Apr 2023)
- Refine your COMMERCIALIZATION STRATEGY to translate your prototype to a commercially viable product
- Improve your COMPUTATIONAL STRATEGY to accelerate your R&D
- Strengthen your LEADERSHIP, your RECRUITING & RETAINING, your BUDGET MANAGEMENT, your PARTNERSHIP and NEGOTIATION skills
WHY you should apply
The SBC Catalyser programme provides:
- A comprehensive commercial strategy to go from prototype to commercially viable product
- A clear execution plan to translate the strategy into action
- Support to understand and embed digital and data technologies into your workflow
- A strategically aware leadership team, able to evolve their commercialisation strategies in response to changes in markets and technologies
- An extended network across the SBC ecosystem; enabling teams to talk to key customers, partners, suppliers and investors
- An enhanced company profile
- Improved chances of getting the right funding, investment and lab space
HOW to achieve your goals
The programme includes:
- Strategy profiling using a range of specialist tools
- Commercialisation strategy development workshops focused on the 12 vectors of growth including: positioning, funding, market, IP management, manufacturing, distribution, human capital management
- 15 sessions over 8 weeks, with panel discussions involving Benevolent AI, Cambridge Innovation Capital, Start Codon, CGT Catapult, Department of Business and Trade, IQVIA, Redx Pharma, Intellegens, Multiply AI, Virtarka and more.
- Being part of the SBC campus and its community including GSK, the Cell and Gene Therapy Catapult (CGTC) and over 40 other growing therapeutics companies
- Access to a world class team of mentors and experts, investors and partners
- Demo Day and Partnering opportunities
WHO you are
- You are developing therapeutic innovations
- You have already built a proof of concept and you are planning to create the first commercially viable product
- You have integrated digital and data technologies (ie ML/AI) in your R&D workflow, or you are planning to integrate them
- You have an existing presence in the UK, or you are planning to establish a presence in the UK
- You have an ambitious leadership team of at least 2-3 that can commit to full participation in the programme, including in-person activities at SBC on the first day (23rd May) and the last 2 days (13-14th July).
WHO we are
- Campus of 40+ therapeutics companies and largest cluster of CGT companies in Europe
- Companies based at SBC have raised more than £2.9bn since SBC's birth in 2012
- Our campus also includes GSK, LifeArc, CGTC and Cytiva
- We provide lab-space, office-space and business development support to our occupiers
- Our Lab Hotel provides free lab-space for 6 months to 4 selected early-stage companies
Read our Economic Impact Assessment report for more information.
Cohort: 10 startups
Cost: There is no cost and no equity will be taken
Programme timeline:
- Applications Deadline: 21st April 2023
- Core Programme: 8 weeks between 23rd May - 14th July 2023
- Continuous Support and Access to SBC Network: 1st June 2023 – 31st May 2024
Format: Hybrid
- 1st day (23rd May) - In person at SBC
- 1-8th week - Online (2 sessions each week)
- Last 2 days (13-14th July) - In person at SBC
Delivered in Collaboration with:
2021 Cohort ("DATA programme")
-
A self-service analytics platform that empowers biologists to perform complex analysis and visualisation. -
Biotx.ai delivers predictive biomarkers as a basis for decision support in precision medicine. -
Enedra is harnessing the power of synthetic lethality and advanced computational Systems Biology to create therapeutics. -
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor (TCR)- based cancer immunotherapies. -
GlamorousAI is AI-first preclinical biotech focusing on the discovery of novel chemistry for challenging targets. -
Human Centric Drug Discovery helps patients with central nervous disorders by making it easier to develop drugs for their diseases. -
iLoF is working to enable a new era of personalised medicine, by using AI and photonics to build a cloud-based ... -
Kantify has developed ZeptoNet - a novel AI technology that can perform in silico high-throughput screening... -
Micrographia Bio is a next generation life sciences company focused on applying machine learning to microscopy. -
Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes. -
The first flexible, open platform built for scientists. Structured experimental data, analytics and lab management. -
Rahko is unlocking quantum drug discovery. Drug discovery is slow, expensive and low precision. -
With the primary focus in Parkinson’s disease, Solvemed Group leverages its proprietary machine learning technology. -
Svastia offers clinical decision support for cancer treatment selection and relapse prediction. -
Following tumour exome sequencing, Vivan Therapeutics generates fruit fly avatars of patients incorporating tumourigenic mutations.
Be part of SBC Catalyser Programme!
Spaces are limited to a maximum of 10 companies per cohort. Contact Marco to know more or to apply.
Contact MarcoCopyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.